Avinger (NASDAQ:AVGR) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Avinger (NASDAQ:AVGR) in a research report sent to investors on Friday. The brokerage issued a hold rating on the medical device company’s stock.

Avinger Stock Performance

Shares of AVGR opened at $0.83 on Friday. The firm has a fifty day moving average of $1.03 and a 200-day moving average of $1.91. The company has a market cap of $1.41 million, a price-to-earnings ratio of -0.05 and a beta of 1.17. Avinger has a 1 year low of $0.76 and a 1 year high of $5.45.

Avinger (NASDAQ:AVGR) last posted its earnings results on Thursday, August 8th. The medical device company reported ($2.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($2.39). The business had revenue of $1.85 million for the quarter, compared to analysts’ expectations of $2.55 million. Analysts predict that Avinger will post -4.69 EPS for the current year.

Institutional Trading of Avinger

A hedge fund recently bought a new stake in Avinger stock. Armistice Capital LLC purchased a new stake in shares of Avinger, Inc. (NASDAQ:AVGR) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 43,747 shares of the medical device company’s stock, valued at approximately $81,000. Armistice Capital LLC owned 2.57% of Avinger as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 18.30% of the company’s stock.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.